Physician profile
Francesca Perugini
NPI 1891746772
$2,043.53
in general payments reported to CMS, 2019-2025
29 companies · $69.94 in 2025
The $69.94 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $471 · 2020: $105 · 2021: $154 · 2022: $431 · 2023: $647 · 2024: $166 · 2025: $69.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $783 · Consulting Fee: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $782.88 |
| Consulting Fee | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celularity INC. | $300.00 | 2019 | |
| Astellas Pharma US INC | $213.08 | 2019-2024 | Veozah, Myrbetriq |
| Abbvie INC. | $181.31 | 2019-2023 | |
| Pfizer INC. | $165.15 | 2019-2024 | |
| Exeltis, USA INC. | $150.31 | 2021-2025 | Slynd |
| Organon LLC | $142.68 | 2022-2024 | Nexplanon, Nuvaring |
| Gynesonics, INC. | $120.48 | 2022-2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Biohaven Pharmaceutical Holding Company LTD. | $100.00 | 2023 | |
| Ascend Therapeutics US, LLC | $96.40 | 2022-2023 | |
| Amgen INC. | $74.01 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $48.96 | 2023-2025 | Myfembree |
| Ethicon US, LLC | $47.90 | 2019-2023 | |
| Shield Therapeutics INC | $42.66 | 2023 | Accrufer |
| Myovant Sciences INC. | $36.84 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.74 | 2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Channel Medsystems, INC. | $33.05 | 2023 | |
| Therapeuticsmd, INC. | $31.47 | 2022 | |
| Innovation Technologies INC | $24.37 | 2023 | Irrisept |
| Agile Therapeutics, INC. | $24.25 | 2021 | |
| Merck Sharp & Dohme LLC | $22.91 | 2019 | |
| Minerva Surgical, INC | $22.79 | 2022 | |
| Integra Lifesciences Corporation | $21.20 | 2025 | Duraseal Exact Spinal Sealant System, Cusa Clarity, Codman Hakim |
| Aspira Women'S Health INC | $20.94 | 2020 | |
| Mayne Pharma Commercial LLC | $20.10 | 2022 | |
| Evofem Biosciences, INC. | $16.24 | 2021 | |
| Millicent US INC | $15.56 | 2025 | Femring, Intrarosa |
| Pacira Pharmaceuticals Incorporated | $13.31 | 2020 | |
| Duchesnay USA Incorporated | $11.94 | 2019 | |
| Meditrina | $11.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francesca Perugini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.